Mitosis-targeted anti-cancer therapies : where they stand

The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effecti...

Full description

Saved in:
Bibliographic Details
Main Authors: Chan, K.-S., Li, H.-Y., Koh, Cheng Gee
Other Authors: School of Biological Sciences
Format: Article
Published: 2013
Subjects:
Online Access:https://hdl.handle.net/10356/99097
http://hdl.handle.net/10220/12878
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
id sg-ntu-dr.10356-99097
record_format dspace
spelling sg-ntu-dr.10356-990972022-06-07T00:25:32Z Mitosis-targeted anti-cancer therapies : where they stand Chan, K.-S. Li, H.-Y. Koh, Cheng Gee School of Biological Sciences DRNTU::Science::Biological sciences The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body’s response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies. 2013-08-02T04:17:18Z 2019-12-06T20:03:21Z 2013-08-02T04:17:18Z 2019-12-06T20:03:21Z 2012 2012 Journal Article Chan, K. S., Koh, C. G., & Li, H. Y. (2012). Mitosis-targeted anti-cancer therapies: where they stand. Cell death and disease, 3(10). 2041-4889 https://hdl.handle.net/10356/99097 http://hdl.handle.net/10220/12878 10.1038/cddis.2012.148 23076219 Cell death and disease
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
topic DRNTU::Science::Biological sciences
spellingShingle DRNTU::Science::Biological sciences
Chan, K.-S.
Li, H.-Y.
Koh, Cheng Gee
Mitosis-targeted anti-cancer therapies : where they stand
description The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body’s response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies.
author2 School of Biological Sciences
author_facet School of Biological Sciences
Chan, K.-S.
Li, H.-Y.
Koh, Cheng Gee
format Article
author Chan, K.-S.
Li, H.-Y.
Koh, Cheng Gee
author_sort Chan, K.-S.
title Mitosis-targeted anti-cancer therapies : where they stand
title_short Mitosis-targeted anti-cancer therapies : where they stand
title_full Mitosis-targeted anti-cancer therapies : where they stand
title_fullStr Mitosis-targeted anti-cancer therapies : where they stand
title_full_unstemmed Mitosis-targeted anti-cancer therapies : where they stand
title_sort mitosis-targeted anti-cancer therapies : where they stand
publishDate 2013
url https://hdl.handle.net/10356/99097
http://hdl.handle.net/10220/12878
_version_ 1735491135128731648